Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: Placebo-controlled double-blind study of estradiol and risedronate: N01C8

Ann E. Kearns, Donald W Northfelt, Amylou Dueck, Pamela J. Atherton, Shaker R. Dakhil, Kendrith M. Rowland, Jyotsna Fuloria, Patrick J. Flynn, Todor Dentchev, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer. Materials and methods: This is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year. Results: No statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power. Conclusions: Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalSupportive Care in Cancer
Volume18
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Double-Blind Method
Androgens
Osteoporosis
Estradiol
Prostatic Neoplasms
Placebos
Bone Density
Pelvic Bones
Gynecomastia
Bone and Bones
Prescription Drugs
Therapeutics
Vitamin D
Estrogens
Breast
Randomized Controlled Trials
Exercise
Calcium
Risedronate Sodium
Population

Keywords

  • Androgen deprivation therapy
  • Estradiol
  • Osteoporosis
  • Prostate cancer
  • Risedronate

ASJC Scopus subject areas

  • Oncology

Cite this

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy : Placebo-controlled double-blind study of estradiol and risedronate: N01C8. / Kearns, Ann E.; Northfelt, Donald W; Dueck, Amylou; Atherton, Pamela J.; Dakhil, Shaker R.; Rowland, Kendrith M.; Fuloria, Jyotsna; Flynn, Patrick J.; Dentchev, Todor; Loprinzi, Charles Lawrence.

In: Supportive Care in Cancer, Vol. 18, No. 3, 03.2010, p. 321-328.

Research output: Contribution to journalArticle

Kearns, Ann E. ; Northfelt, Donald W ; Dueck, Amylou ; Atherton, Pamela J. ; Dakhil, Shaker R. ; Rowland, Kendrith M. ; Fuloria, Jyotsna ; Flynn, Patrick J. ; Dentchev, Todor ; Loprinzi, Charles Lawrence. / Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy : Placebo-controlled double-blind study of estradiol and risedronate: N01C8. In: Supportive Care in Cancer. 2010 ; Vol. 18, No. 3. pp. 321-328.
@article{cc128e7840c7413faea79733f8b76036,
title = "Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: Placebo-controlled double-blind study of estradiol and risedronate: N01C8",
abstract = "Purpose: The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer. Materials and methods: This is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year. Results: No statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power. Conclusions: Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.",
keywords = "Androgen deprivation therapy, Estradiol, Osteoporosis, Prostate cancer, Risedronate",
author = "Kearns, {Ann E.} and Northfelt, {Donald W} and Amylou Dueck and Atherton, {Pamela J.} and Dakhil, {Shaker R.} and Rowland, {Kendrith M.} and Jyotsna Fuloria and Flynn, {Patrick J.} and Todor Dentchev and Loprinzi, {Charles Lawrence}",
year = "2010",
month = "3",
doi = "10.1007/s00520-009-0655-x",
language = "English (US)",
volume = "18",
pages = "321--328",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy

T2 - Placebo-controlled double-blind study of estradiol and risedronate: N01C8

AU - Kearns, Ann E.

AU - Northfelt, Donald W

AU - Dueck, Amylou

AU - Atherton, Pamela J.

AU - Dakhil, Shaker R.

AU - Rowland, Kendrith M.

AU - Fuloria, Jyotsna

AU - Flynn, Patrick J.

AU - Dentchev, Todor

AU - Loprinzi, Charles Lawrence

PY - 2010/3

Y1 - 2010/3

N2 - Purpose: The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer. Materials and methods: This is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year. Results: No statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power. Conclusions: Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.

AB - Purpose: The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer. Materials and methods: This is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year. Results: No statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power. Conclusions: Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.

KW - Androgen deprivation therapy

KW - Estradiol

KW - Osteoporosis

KW - Prostate cancer

KW - Risedronate

UR - http://www.scopus.com/inward/record.url?scp=77949273411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949273411&partnerID=8YFLogxK

U2 - 10.1007/s00520-009-0655-x

DO - 10.1007/s00520-009-0655-x

M3 - Article

C2 - 19468757

AN - SCOPUS:77949273411

VL - 18

SP - 321

EP - 328

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -